Wang S, et al. - This multicenter cohort study assessed the effect of tolvaptan on the 6-month survival of decompensated cirrhotic patients both with and without hyponatremia. Participants in the study were 249 decompensated cirrhotic patients with or without hyponatremia. In most decompensated cirrhotic hyponatremia patients with resolved serum sodium, tolvaptan improved short-term survival. It was noted that 6-month survival rate was 81.32% in tolvaptan-treated hyponatremia patients with resolved serum sodium. On the other hand, survival was only 24% in those with unresolved serum sodium. In decompensated cirrhotic patients without hyponatremia, Tolvaptan did not alter serum sodium levels and survival outcome.